Your care
is our core
Everybody in his life is eventually confronted with dangerous forms of cancer, as a patient or as a relative or a friend fighting this devastating and unpredictable disease. Although, due to all progression of treatment over the last decades which means that survival rates improved, there are still various forms of cancer which are hard to treat which means the patient runs out of options.
Adding new options for treatment
Our technology works in situations where the tumor or metastasis cannot be resected or treated with conventional radiotherapy and where other therapies like chemo- or immuno-therapy do not have the desired effect on the cancer cells. Due to the targeted method, the side-effects for the patient are relatively low while at the same time the delivered dose of radiation in the solid tumor or metastasis is relatively high.
Coretag is partnering with different medical specialists and Principal Investigators engaging with their top institutions to execute the different clinical trials before our treatment can become available for you as a patient. In order to be able to add its new treatment options to the toolkit of medical specialists, we have to obtain approval from EMA in Europe and FDA in the United States.
It is our goal and mission to arrange this approval as soon as possible which means we can start making lives longer and create precious extra time for you, your family and your friends.
In case you want to know more about our treatments and our developments, please subscribe for our Newsletter below. For specific questions you always can reach out to us, please send u an email for more information about our goals and treatment.
Support for patients
Get to the core
At Coretag we develop targeted radiotherapies which become effective in situations where other treatment options are fading out. By tagging the core of solid tumors and metastasis with lethal nuclear isotopes we are able to kill the surrounding living cancer cells with the goal to slow down the development of solid tumors and metastasis.
